



02-02-05

IFW

Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	10/807,884
		Filing Date	March 24, 2004
		First Named Inventor	Kevin A. Babiak, et al.
		Group Art Unit	1624
		Examiner Name	TBA
Total Number of Pages in This Submission		Attorney Docket Number	3589/1/US 31388A/USA (6794-000041/US)

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Postcard
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Form 1449
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	25 References
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	David M. Gryte, Reg. No. 41,809 Harness, Dickey & Pierce, P.L.C.
Signature	
Date	February 1, 2005


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being hand-delivered to the Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name	David M. Gryte
Signature	
Date	February 1, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EV 317349941 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kevin A. Babiak, et al.
Serial No: 10/807,884
Filed: March 24, 2004
For: Process for Making Alpha-Substituted Hydroxamic Acids
Confirmation No: 5589
Group Art Unit: 1624
Examiner: TBA
Attorney Ref: 3589/1/US
Pfizer Ref: 31388A/USA
HDP Ref: 6794-000041/US

February 1, 2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing the Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this supplemental information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents are not admitting that such documents are necessarily relevant or prior art.

Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

EW 317265Q:1

Supplemental Information Disclosure Statement

Appl. No. 10/807,884

February 1, 2005

Applicants request early and favorable consideration of this patent application.

* * * * *

Applicants believe that they do not owe any fee in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

The Examiner is requested to call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,




David M. Gryte, PTO Reg. No. 41,809
Harness, Dickey & Pierce
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **February 1, 2005** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.



DMG/JPG/PML
enclosures



HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
		3589/1/US (Pfizer Ref. 31388A/USA)	10/807,884
		APPLICANT	
		Kevin A. Babiak, et al.	
Sheet 1 of 2		FILING DATE	GROUP
		March 24, 2004	1624

U.S. Patent Documents

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) filing date

FOREIGN Patent Documents

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
26.		WO 99/09000	02/25/99	PCT	C07C 235/00		
27.		WO 99/25687	5/27/99	PCT	C07D 211/66		
28.		WO 00/46221	8/10/00	PCT	C07D 405/12		
29.		WO 00/50396	8/31/00	PCT	C07D 211/66		
30.		WO 00/59874	10/12/00	PCT	C07C 259/06		
31.		WO 00/69821	11/23/00	PCT	C07D 211/66		
32.		WO 02/092588	11/21/00	PCT	C07D 309/08		
33.		WO 03/007930	1/30/03	PCT	A61K 31/166		
34.		WO 03/045944	06/05/03	PCT	C07D 405/12		
35.		WO 03/091247	11/6/03	PCT	C07D 407/12		
36.		PCT/US2004/036666	Filed 11/3/04	PCT	TBA		
37.		EP 0 780 386	6/25/97	Europe	C07D 309/08		
38.		EP 1 081 137	3/7/01	Europe	C07D 211/96		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EW 31/6/2004

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET NO.	SERIAL NO.
3589/1/US (Pfizer Ref. 31388A/USA)	10/807,884
APPLICANT	
Kevin A. Babiak, et al.	
FILING DATE	GROUP
March 24, 2004	1624

Other Documents (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

Ref. Desig.	Examiner's Initials	
39.		Brown, P.D., "Synthetic Inhibitors of Matrix Metalloproteinases," in <i>Matrix Metalloproteinases</i> , pp. 243-61 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).
40.		Denis et al., <i>Matrix metalloproteinase inhibitors: Present achievements and future prospects</i> , INVEST. NEW DRUGS, 15:175-185 (1997).
41.		Floyd et al., <i>A Method for the Synthesis of Hydrazamic Acids on Solid Phase</i> , TETRAHEDRON LETTERS, 27(64):8045-8048 (1996).
42.		Gearing et al., <i>Processing of tumour necrosis factor-α precursor by metalloproteinases</i> , NATURE, 370:555-557 (1994).
43.		Gu et al., S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death, SCIENCE, 297:1186-90 (2002).
44.		McGeehan et al., <i>Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor</i> , NATURE, 370:558-561 (1994).
45.		Mitchell et al., <i>Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage</i> , J. CLIN. INVEST. 97(3):761-768 (1996).
46.		Rasmussen et al., <i>Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat</i> , PHARMACOL. THER., 75(1):69-75 (1997).
47.		Reboul et al., <i>The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes</i> , J. CLIN. INVEST., 97(9):2011-2019 (1996).
48.		Schwartz et al., <i>Synthetic inhibitors of bacterial and mammalian interstitial collagenases</i> , PROG. IN MED. CHEM., 29:271-334 (1992).
49.		Tang, B. L., <i>ADAMTS: A Novel Family of Extracellular Matrix Proteases</i> , INT. J. BIOCHEM. CELL BIO., 33(11):33-44 (2001).
50.		Woessner, J.F., "The Matrix Metalloprotease Family" in <i>Matrix Metalloproteinases</i> , pp.1-14 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.